SOPHiA GENETICS Reaffirms FY23 Full-Year Reported Revenue Growth At Or Above 30%; Full-Year Constant Currency Revenue Growth Excluding COVID-19-Related Revenue 30%-35%
Portfolio Pulse from Benzinga Newsdesk
SOPHiA GENETICS has reaffirmed its FY23 full-year reported revenue growth at or above 30%. The company also expects full-year constant currency revenue growth, excluding COVID-19-related revenue, to be between 30% and 35%.
November 07, 2023 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SOPHiA GENETICS has reaffirmed its FY23 full-year reported revenue growth at or above 30%, which could positively impact its stock price.
Revenue growth is a key indicator of a company's financial health and future prospects. SOPHiA GENETICS reaffirming its FY23 full-year reported revenue growth at or above 30% indicates strong financial performance and could lead to increased investor confidence, potentially driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100